CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 42 enrolled
Drug / intervention
Placebo +4 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02573233
NCT02573233Phase 2Completed
CompareCT.gov

An Exploratory, Double-blind, Placebo-controlled Study of the Effects of Dupilumab on Airway Inflammation of Adults With Persistent Asthma

Sanofi·interventional·Posted Oct 9, 2015·Updated Apr 4, 2022

In Brief

A Phase 2 clinical trial evaluating Placebo, Dupilumab SAR231893/REGN668, and 3 other interventions for Asthma. Completed, enrolled 42 participants across 16 sites in 6 countries.

Detailed Summary

Primary Objective: To evaluate the effect of dupilumab, compared to placebo, on airway inflammation in participants with persistent asthma. Secondary Objective: To assess the safety, tolerability, and immunogenicity of dupilumab compared to placebo.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAsthma
CountriesCanada, Denmark, Germany, Sweden, United Kingdom, United States
CollaboratorsRegeneron Pharmaceuticals

Timeline

Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedOct 9, 2015
Enrollment StartJan 27, 2016
Primary CompletionJan 3, 2018
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 10.7 years ago

Interventions

Placebodrug

Pharmaceutical form:solution Route of administration: subcutaneous

Dupilumab SAR231893/REGN668drug

Pharmaceutical form:solution Route of administration: subcutaneous

fluticasone propionate and salmeteroldrug

Pharmaceutical form:inhalation aerosol, inhalation powder Route of administration: inhaled

budesonide and formoteroldrug

Pharmaceutical form:inhalation aerosol Route of administration: inhaled

mometasone furoate and formoteroldrug

Pharmaceutical form:inhalation aerosol Route of administration: inhaled